Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 250 movers: CSR jumps as chip sales impress

Thu, 29th Oct 2009 12:11

CSR, which makes chips for Bluetooth and Global Positioning System (GPS) devices, is sharply higher after third quarter results were better than expected.Pre-tax profits for the period totalled $10.7m compared with a $30.8m over the same period the previous year. Revenues climbed to $219.9m from $205.5m. Bluetooth accounted for $150.4m, GPS for $59.5m.At the time of its second quarter results, CSR issued third quarter guidance of $195m to $215m for revenue. The median forecast of investment analysts' revenue forecasts was $208m.Qinetiq climbs after saying the boss of defence technology group QinetiQ, Graham Love, is being replaced by the former chief of banknote printer De La Rue, Leo Quinn, after eight years at the company.Investment management firm Evolution Group is going well after saying it expects to beat full year profit forecasts this year on the back of strong trading across all of its divisions. Revenues from the Investment Banking arm in the second half of 2009 will be at least double those seen in the first half, reflecting the increased corporate activity.Elsewhere in finance, Fund manager Henderson said assets under management increased 9% to £57.7bn in the third quarter to 30 September 2009 as market conditions continue to improve.National Express is sharply lower after the hard-up bus and train group said it has ended all takeover discussions with rival Stagecoach in order to focus on completing an equity fundraising by the end of this year.Shares in Yell fall back after the cash-strapped Yellow Pages directory publisher Yell Group again extended the deadline for its refinancing. The company, which is looking to restructure £3.8bn of debt, extended the deadline for the third time this week after last night's cut-off passed without success.FTSE 250 - RisersCSR (CSR) 446.60p +11.07%QinetiQ Group (QQ.) 154.80p +8.33%Taylor Wimpey (TW.) 37.77p +5.77%Aquarius Platinum Ltd. (AQP) 274.00p +5.71%Redrow (RDW) 139.80p +5.43%Evolution Group (EVG) 158.50p +4.55%Victrex (VCT) 784.50p +4.32%Barratt Developments (BDEV) 135.30p +4.24%BlueBay Asset Management (BBAY) 368.40p +3.98%Tomkins (TOMK) 162.60p +3.90%FTSE 250 - FallersNational Express Group (NEX) 328.10p -10.01%Laird (LRD) 163.20p -9.33%PartyGaming (PRTY) 221.50p -5.54%Henderson Group (HGG) 127.40p -4.64%PayPoint (PAY) 448.50p -4.17%Melrose Resources (MRS) 357.60p -2.85%Yell Group (YELL) 45.04p -2.81%Imagination Technologies (IMG) 202.50p -2.64%Debenhams (DEB) 77.50p -2.52%PV Crystalox Solar (PVCS) 65.55p -2.16%
More News
22 Mar 2021 14:32

IN BRIEF: Evgen Pharma names Helen Kuhlman as chief business officer

IN BRIEF: Evgen Pharma names Helen Kuhlman as chief business officer

Read more
22 Mar 2021 09:08

Evgen appoints Helen Kuhlman as chief business officer

(Sharecast News) - Clinical-stage drug development company Evgen announced on Monday that Helen Kuhlman had been appointed to the post of chief business officer, taking up the role from 1 April.

Read more
11 Mar 2021 20:08

IN BRIEF: Evgen says no patient safety concerns in STAR Covid-19 trial

IN BRIEF: Evgen says no patient safety concerns in STAR Covid-19 trial

Read more
11 Mar 2021 15:12

Evgen Covid-19 trial given all-clear on safety and data

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Thursday that after a review of the first 60 patients enrolled, the data safety monitoring committee for the 'STAR' Covid-19 trial had concluded that there were no concerns over patient safety or data quality that would prevent its continuation.

Read more
3 Mar 2021 20:16

TRADING UPDATES: Cambria drives on amid virus; Argo crypto mining up

TRADING UPDATES: Cambria drives on amid virus; Argo crypto mining up

Read more
24 Feb 2021 16:09

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
17 Feb 2021 15:10

Evgen makes progress with recruitment in 'STAR' trial

(Sharecast News) - Clinical stage drug development company Evgen Pharma said on Wednesday that a total of 102 patients had been recruited and randomised to the 'STAR', or 'SFX-01 Treatment for Acute Respiratory infections', trial.

Read more
17 Feb 2021 11:15

IN BRIEF: Evgen Pharma Recruits Over 100 For Respiratory Drug Trial

IN BRIEF: Evgen Pharma Recruits Over 100 For Respiratory Drug Trial

Read more
3 Feb 2021 11:49

IN BRIEF: Intuitive Investments Buys Shares in Evgen For GBP175,000

IN BRIEF: Intuitive Investments Buys Shares in Evgen For GBP175,000

Read more
2 Feb 2021 17:45

IN BRIEF: Evgen Pharma's GBP11 Fundraise To Support Lead Candidate

IN BRIEF: Evgen Pharma's GBP11 Fundraise To Support Lead Candidate

Read more
22 Jan 2021 08:53

Evgen Shares Rise On Further Positive Test Results For SFX-01

Evgen Shares Rise On Further Positive Test Results For SFX-01

Read more
21 Jan 2021 13:20

IN BRIEF: Evgen Pharma Notes Positive Preclinical Data For SFX-01

IN BRIEF: Evgen Pharma Notes Positive Preclinical Data For SFX-01

Read more
19 Jan 2021 17:34

IN BRIEF: Evgen Pharma Recruits Patients For STAR-Covid-19 Trial

IN BRIEF: Evgen Pharma Recruits Patients For STAR-Covid-19 Trial

Read more
10 Dec 2020 17:07

UK EARNINGS SUMMARY: Character Group Lowers Dividend As Profit Drops

UK EARNINGS SUMMARY: Character Group Lowers Dividend As Profit Drops

Read more
10 Dec 2020 15:45

Evgen Pharma performs in line with forecasts in first half

(Sharecast News) - Clinical-stage drug development company Evgen Pharma reported financial performance in line with its expectations in its first half on Thursday, with revenue coming in at £0.19m, compared to nil a year earlier.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.